Vividion Therapeutics Expands Clinical Development of WRN Inhibitor VVD-214 with Phase 2 Combination Study in First-Line Patients with Advanced Colorectal Cancer

San Diego, CA, USA, and Berlin, Germany, October 15, 2026 –Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company and a wholly owned and independently operated subsidiary of Bayer AG, today announced that the first patient has been dosed in a Phase 2 clinical trial of VVD-214, an investigational oral inhibitor of Werner helicase (WRN). The […] The post Vividion Therapeutics Expands Clinical Development of WRN Inhibitor VVD-214 with Phase 2 Combination Study in First-Line Patients with Advanced Colorectal Cancer appeared first on Vividion Therapeutics .